Definium Study Reveals High Treatment Discontinuation Rates in GAD Patients — Definium Therapeutics, Inc.

Event summary

Definium Therapeutics published a healthcare claims study in CNS Spectrums showing high rates of treatment discontinuation and switching among GAD patients.
55% of newly diagnosed GAD patients discontinued their initial pharmacotherapy, with 28% adding or switching treatments.
Median time to discontinuation was 84 days for newly diagnosed patients and 119 days for established patients.
The study analyzed data from over 1.2 million patients using the Komodo Healthcare Map™ database.

The big picture

The study highlights significant unmet needs in GAD treatment, with high rates of discontinuation and switching underscoring the need for more effective and tolerable therapies. Definium Therapeutics is positioning itself to address this gap with its pipeline of innovative treatments aimed at psychiatric and neurological disorders. The findings could accelerate regulatory interest and investor attention in the mental health sector.

What we're watching

Treatment Innovation: Whether Definium can develop new GAD treatments that address the high discontinuation and switching rates observed in the study.
Market Opportunity: The pace at which Definium can capitalize on the unmet need in GAD treatment, given the lack of innovation since 2007.
Regulatory Pathway: How Definium's therapeutic candidates will navigate regulatory approvals to bring new treatments to market.